Asset profile
EVO301
Protein / enzyme therapeutic
Evidence outlook · lead readout
NCT06723405 · Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06723405: The trial randomized 71 participants to EVO301 or placebo and masked participants, investigators, and outcome assessors. Its primary endpoint was the clinical EASI score at 12 weeks, but no results or statistical comparison for that endpoint are available.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.